BioCentury
ARTICLE | Clinical News

VXA-G1.1-NN: Ph I data

March 17, 2017 1:02 PM UTC

A double-blind, placebo-controlled, U.S. Phase I trial in 66 healthy volunteers showed that single doses of 1×1010 and 1×1011 IU oral VXA-G1.1-NN both met the primary endpoint of safety. Specifically,...

BCIQ Company Profiles

Vaxart Inc.